Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The plasma fractionation market size was reported at US$ 37.87 billion in 2025 and is expected to rise to US$ 40.73 billion in 2026. According to forecasts, it will grow at a CAGR of 7.54% to reach US$ 78.34 billion by 2035.
Plasma fractionation is a complex process to separate blood plasma into individual components, predominantly protein which includes clotting factors, albumin, immunoglobulins and fibrinogens, other components are enzymes and antibodies with phenomenal therapeutical values. Plasma fractionation is widely used in pharmaceutical research to treat chronic diseases. The worldwide rising demand for plasma derivatives due to increased immune disease, coagulation disorders and genetic defects is fuelling the market growth.
Plasma fractionation is the process of separating human plasma into specific proteins used to manufacture therapeutic products such as immunoglobulins, albumin, and coagulation factors. The market is growing as demand-driven medicines increase across immunodeficiency, bleeding, and critical-care applications. A key trend is the expansion of plasma collection networks and greater investments in fractionation capacity to strengthen supply security. Technological advancements in purification, chromatography, viral inactivation, and protein separation are improving product quality, yield, and manufacturing efficiency. Future opportunities are emerging from recombinant and next-generation plasma-derived therapies, personalized treatment approaches, and improved access to rare-disease medicines. Increasing diagnosis of immune and bleeding disorders, rising healthcare expenditure, growing awareness of plasma therapies, and pharmaceutical investments in manufacturing infrastructure are supporting market expansion. Automation and advanced process monitoring are also enhancing production consistency and operational efficiency.
Chromatography is the Future of Plasma Fractionation Market
The chromatography-based method for plasma separation rapidly gaining popularity as offers gradual improvement, improves purity and enables the production of new classes of therapeutics. Plasma contains over 120 varieties of protein. When these proteins are extracted pure and concentrated, they can create life-saving therapeutics which are crucial for the treatment of several diseases such as immune deficiencies and bleeding disorders.
Even today, modern plasma fractionation technology relies on the original, ethanol-based protocol which is mostly used to isolate albumin. To produce novel plasma products which can be used to treat protein deficiencies, it is essential to implement chromatographic techniques. This precise technique has the ability to capture even trace protein. With the help of ion-exchange chromatography (IEC), proteins at their original pH and ionic strength, even fragile proteins (such as coagulation factors, anticoagulants, and protease inhibitors) are preserved and isolated.
Risk of Sepsis: Market’s Major Restraint
A study published in the journal Science Translational Medicine mentions a pattern developing with certain blood plasma protein levels that can lead to the development of sepsis in patients. A team of medical researchers analysed the plasma profiles of hundreds of ICU patients who had developed sepsis. When the body shows dysregulated response to infection, it the known as sepsis condition. It is considered a life-threatening condition as it leads to multiple organ failure. Every year in the United Kingdom approximately 50,000 deaths are noted due to sepsis.
The researchers drew out plasma samples from 16,000 patients and measured protein levels for plasma proteome using tandem mass spectrometry and liquid chromatography on 2,600 samples. The results provide a general profile which is used to identify patients at risk.
Growth in Plasma-derived Products
The increasing incidence of chronic disease is increasing the demand for plasma-derived treatment options. At the same time, they are also being used for the treatment of autoimmune and neurological disorders. Moreover, the presence of limited alternatives is increasing their use. Thus, to deal with this growing demand, the use as well as the demand for plasma fractionation facilities increases. At the same time, the growing developments in plasma-derived therapies also contribute to the same. Thus, this promotes the plasma fractionation market growth.
In June 2025, to expand the plasma fractionation product storage facilities across Andong, 12 billion won will be invested by SK Plasma. To establish freezing facilities and refrigeration facilities near its existing Andong fractionation center for storing raw plasma and finished pharmaceuticals, respectively, this investment will be utilized.
| Key Elements | Scope |
| Market Size in 2025 | USD 37.87 Billion |
| Projected Market Size in 2035 | USD 78.34 Billion |
| CAGR (2026 - 2035) | 7.54% |
| Leading Region | North America |
| Key Applications | Immunodeficiency treatment, Hemophilia, Critical care, Neurology, Autoimmune disorders, Liver disease, Trauma care |
| Primary End Users | Hospitals, Specialty Clinics, Blood Banks, Infusion Centers, Retail & Specialty Pharmacies |
| Key Challenges | Limited plasma donor availability, lengthy manufacturing cycle, strict regulatory compliance, high production costs, supply-demand imbalance |
| Market Segmentation | By Type, By Application, By Region |
| Top Key Players | Syntegon, CSL Behring, Grifols Therapeutics, Mitsubishi Tanabe, Octapharma AG, Hualan Bio, Kedrion S.p.A, Takeda Pharmaceutical Company Ltd., LFB Group, Intas Pharmaceuticals Ltd., Biotest AG, Bio Product Laboratory Ltd. |
By type, Immune Globulin dominated the plasma fractionation market in 2025. The growth of this segment is noticed by plasma-derived immunoglobulins are provided with a new narrative in the healthcare industry for a wide range of autoimmune inflammatory diseases. Immune globulin is needed for a patient who cannot make enough antibodies. This provides externally sourced antibodies for recovery.
The Coagulation Factor segment is expected to grow significantly in the plasma fractionation market during the forecast period of 2024 to 2034. The expansion of this segment is observed due to its ability to stop bleeding when injured. It includes a system of proteins that controls the conversion of soluble plasma fibrinogen to fibrin, an insoluble polymer that forms a gel network to stop bleeding.
By application, the hospital segment stood dominant in the plasma fractionation market in 2025. The dominance is observed due to the wide utilization of plasma at hospitals for emergency cases to boost blood volume in trauma patients, prevent shock and help with blood clotting. Healthcare providers supply various plasma-derived medicinal products to hospitals and other healthcare facilities for the treatment of patients with immune deficiency disorders, immunodeficiency virus, hepatitis virus and many more.
The retail pharmacy segment is anticipated to grow with the highest CAGR in the plasma fractionation market during the studied years. Pharmaceutical companies extract components from raw human plasma using centrifugation, depth filtration and chromatographic methods. The manufacturing process is carried out to produce effective and safe drugs.
North America dominated the global plasma fractionation market in 2025. The unites states is the largest supplier of Plasma Fractionation in the world. As US has a policy of paid donors while other countries obtain plasma from volunteers and unpaid donors. Therefore, the rate of plasma collection is less in other countries. Canadian Blood Service uses raw plasma to produce a category of drugs such as plasma protein and related products. Additionally, the three largest plasma product companies in the U.S. – CSL Plasma, Grifols and BioLife, collect over 75% of total plasma for fractionation in the States. That are about 54% more plasma donation centres in the US than there were four years back. With the rising demand for plasma on every basis of 6,500 units, there needs to be a consistent donation rate.
Canada Market Trends
In Canada, 52% of people or their family members require blood or blood products at some point in their lifetime. Canadian Blood Services (CBS) is an NGO that collects and recruits blood, plasma, and platelets at 36 collection sites and more than 14,000 donor clinics annually.
U.S. Leads Through Advanced Plasma Infrastructure
The U.S. plasma fractionation market is significantly growing due to strong demand for plasma-derived therapies, extensive plasma collection networks, and advanced biopharmaceutical manufacturing capabilities. High awareness of immunoglobulin and albumin therapies, increasing diagnosis of immune and bleeding disorders, and substantial healthcare spending support market expansion. Investments in plasma-processing facilities, purification technologies, and supply-chain capacity further strengthen the country’s market growth.
Europe is anticipated to register the fastest growth in the haptic devices market during the forecast period of 2026 to 2035. The growth in this region depends upon the European Union's attainment of open strategic autonomy and improved competitiveness. European Union institutes, governments and businesses are working towards a better understanding of potential vulnerabilities and opportunities to modify policies to ensure a resilient supply of plasma and plasma-derived medicinal products. This action will provide a better solution for the EU and national level to achieve recognition.
UK Market Trends
The National Health Service (NHS) aims to collect 300,000 liters of plasma annually. In July 2023, Octapharma was appointed as the sole fractionator for the UK’s Plasma for Medicines Program. The program was launched to reduce the reliance on external plasma sources and ensure a stable and affordable supply of these products in the UK.
Germany Market Trends
About 2 million people donate blood annually in Germany, accounting for 2-3% of the total population. In March 2023, CSL opened a new $470 million plasma fractionation facility in Marburg, Germany. The state-of-the-art facility was opened to transform human plasma into life-saving medicines.
Asia-Pacific is expected to grow at a considerable rate in the plasma fractionation market in the upcoming period. Numerous government and private organizations launch initiatives and conduct workshops to create awareness about blood and plasma donations among the general public. The rising adoption of advanced technologies to streamline the fractionation process boosts the market. The increasing prevalence of blood-related disorders and the availability of a suitable manufacturing infrastructure drive the market.
India Market Trends
In India, 14.6 million blood are required annually, and there is a shortage of approximately 1 million. Hence, the Indian government promotes blood donation through “Raktdan Amrit Mahotsav”. The E-Rakt Kosh portal is a national repository of blood donors.
China Expands Through Rising Demand for Plasma Therapies
China’s plasma fractionation market is notably expanding due to increasing demand for plasma-derived medicines, growing healthcare expenditure, and improvements in domestic biopharmaceutical manufacturing. Rising awareness of immunodeficiency and bleeding disorders is supporting therapy adoption. Investments in plasma collection infrastructure, fractionation capacity, and advanced purification technologies are further strengthening local production technologies are further strengthening local production capabilities and creating new growth opportunities.
Latin America is expected to grow significantly in the plasma fractionation market during the forecast period. The healthcare sector in Latin America is advancing. They are developing as well as adapting to various advanced treatment options to tackle the growing rates of genetic disorders. This, in turn, is increasing the research and development of plasma-derived therapies for their treatment, which in turn is increasing the demand for plasma fractionation facilities. Thus, the adoption of these facilities and the development of the therapies are being supported by the government initiatives and investments. Thus, this is promoting the market growth.
Brazil Expands Through Growing Demand for Plasma-Derived Therapies
Brazil’s plasma fractionation market is significantly growing due to increasing demand for immunoglobulin, albumin, and clotting-factor therapies. Expanding healthcare access, rising awareness of rare and immune-related disorders, and strengthening domestic biopharmaceutical capabilities are supporting market development. Government efforts to improve plasma collection and processing infrastructure, along with investments in advanced fractionation technologies, are further creating opportunities for market expansion.
Argentina Expands Through Strengthening Plasma Therapeutics
Argentina’s plasma fractionation market is notably expanding due to rising demand for plasma-derived therapies, increasing healthcare needs, and growing awareness of treatments for immune and bleeding disorders. Improvements in plasma collection and processing capabilities are supporting domestic supply. Investments in biotechnology, pharmaceutical manufacturing, and advanced purification technologies are further enhancing production efficiency and creating opportunities for broader access to plasma-based medicines.
| Ecosystem Segment | Representative Participants | Role in the Market |
| Technology Providers | Cytiva, Sartorius, Merck KGaA, Repligen | Chromatography systems, filtration technologies, purification solutions |
| Product Manufacturers | CSL Behring, Grifols, Takeda, Octapharma, Kedrion | Manufacture plasma-derived therapeutic proteins |
| Plasma Collection Providers | CSL Plasma, Grifols Plasma, BioLife Plasma Services, Octapharma Plasma | Collect source plasma for manufacturing |
| CDMOs | SK Plasma, LFB Biomanufacturing | Contract manufacturing and plasma processing |
| Testing & Diagnostics Providers | Roche Diagnostics, Abbott, Bio-Rad Laboratories | Plasma screening, pathogen detection, quality testing |
| Research Institutions | Mayo Clinic, NIH, Canadian Blood Services, NHS Blood and Transplant | Clinical research, plasma science, therapeutic development |
| Equipment Suppliers | Thermo Fisher Scientific, Cytiva, Sartorius | Manufacturing equipment and process technologies |
| End-User Industries | Hospitals, Pharmaceutical Companies, Specialty Clinics, Blood Centers | Administration and utilization of plasma-derived therapies |
In January 2025, financial results were released by Takeda Pharmaceutical Company Limited, which were 3.5 trillion, with an increase of 9.8% year-on-year. Revenue growth was reported. The core operating profit showed JPY 1 trillion, indicating a rise of 16.3% year-on-year and JPY 835 billion, reflecting 90.8% growth, which was reported for operating cash flow. Moreover, significant growth in growth & launch products was observed with 47% of total revenue. There was a global rise in the demand for vaccines, Kudanga with around 10 million doses, while plasma-derived therapies such as albumin and immunoglobulin showed a growth of 2.2% and 11.9%, respectively.
In March 2025, the Biotest Group released its financial results, which reported € 726.2 million in sales, indicating a 6.1 % growth in sales. The sale increased from € 34.9 million to € 62.1 million for their new intravenous immunoglobulin Yimmugo®. Moreover, adjusted EBIT was observed to be € 64.5 million in the past financial year, where € 65 to 85 million is its forecast amount. Additionally, € 46.5 million was noted to be the earnings before taxes (EBT). Similarly, the EAT amounted to € 26.4 million for the 2024 financial year.
| Tier 1 | Tier 2 | Tier 3 | |
| Typical Market Influence | 72% | 20% | 8% |
| Tier 1 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| CSL Behring | King of Prussia, Pennsylvania | United States | Global leader in plasma-derived therapeutics with vertically integrated plasma collection and manufacturing | Immunoglobulins, Albumin, Coagulation Factors, Plasma Collection |
| Grifols | Barcelona, Catalonia | Spain | One of the world's largest plasma companies with extensive collection network | IVIG, Albumin, Alpha-1 Antitrypsin, Plasma Collection |
| Takeda Pharmaceutical Company | Tokyo | Japan | Major global supplier following acquisition of Shire's plasma business | Immunoglobulins, Albumin, Coagulation Factors |
| Tier 2 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Biotest AG | Dreieich, Hesse | Germany | Specialized plasma protein manufacturer with expanding immunoglobulin portfolio | Immunoglobulins, Albumin, Coagulation Factors |
| LFB Group | Les Ulis, Île-de-France | France | European plasma-derived medicines producer focused on rare diseases | Plasma Proteins, Immunoglobulins |
| SK Plasma | Seongnam-si, Gyeonggi-do | South Korea | Leading Asian plasma fractionation company with expanding production capacity | Albumin, IVIG, Coagulation Products |
| Tier 3 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| ADMA Biologics | Ramsey, New Jersey | United States | Rapidly growing specialty plasma-derived biologics company | IVIG, Hyperimmune Globulins |
| Hualan Biological Engineering | Xinxiang, Henan | China | Major Chinese plasma-derived therapeutics manufacturer | Albumin, Immunoglobulins |
| Kamada Ltd. | Rehovot | Israel | Specialist developer of plasma-derived specialty therapeutics | Plasma Protein Therapeutics |
By Type
By Application
By Region
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
